Lattice Certus-NX FPGAs Optimized for Automotive Applications
25.8.2021 23:00:00 EEST | Business Wire | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today expanded its growing portfolio of automotive products with the announcement of versions of the Lattice Certus™-NX FPGA family optimized for infotainment, advanced driver assistance systems (ADAS), and safety-focused applications. Built on the Lattice Nexus™ platform, these new Certus-NX devices combine automotive-grade features with best-in-class I/O density, power efficiency, small size, reliability, instant-on performance, and support for fast PCI Express (PCIe) and Gigabit Ethernet interfaces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210825005002/en/
The Lattice Certus-NX Automotive General Purpose FPGA (Graphic: Business Wire)
“Demand for automotive semiconductors is increasing as the ongoing trends towards automotive system electrification, autonomy, and connectivity have manufacturers looking for ways to deliver the advanced features and user experiences drivers are looking for in their next vehicle,” said Jay Aggarwal, Director of Silicon Product Marketing, Lattice Semiconductor. “With class-leading performance and power efficiency, support for popular I/O standards in a small form factor, and high reliability, our Certus-NX general purpose FPGAs make a compelling silicon platform for the next-generation automotive applications car makers are eager to provide to their customers.”
“As more automotive systems go digital, modern cars have essentially become mobile datacenters. Automotive developers need access to secure and reliable silicon solutions with fast I/O performance to ensure mission-critical automotive systems can perform their functions instantaneously,” said K. Ganesh Rao, Practice Head – FPGA Solutions, Tata Elxsi. “Lattice Certus-NX FPGAs provide the reliability, performance, and feature set we need to make tomorrow’s automotive applications possible.”
The latest Certus-NX FPGAs are ideal for automotive applications like motor control, LED control in in-vehicle infotainment (IVI) systems, in-vehicle networking (IVN), and sensor data co-processing in ADAS applications. Key features of Certus-NX FPGAs include:
- Low power consumption – Up to 4X lower power use than similar FPGAs, with a programmable back bias that enables user-selectable high performance or low power operating modes, depending on the needs of the application.
- Small form factor – Up to 3X smaller with up to 2X the I/O density per mm2 in comparison to similar competing FPGAs.
- Instant-on performance – Ultra-fast device configuration from SPI memory up to 12X faster than similar competing FPGAs, with individual I/O able to configure in just 3 ms, and full-device startup in only 8-14 ms, depending on device capacity.
-
Robust I/O interfacing capability – Lattice’s extensive Certus-NX I/O IP library includes:
- 1.5 Gbps differential I/O with performance up to 70 percent higher than competing FPGAs.
- 5 Gbps PCIe, 1.5 Gbps SGMII, and 1066 Mbps DDR3.
- Automotive certification and high reliability – Certus-NX FPGAs are AEC-Q100 qualified and provide up to 100X better soft error rate (SER) performance than similar FPGAs.
- Authentication and encryption – To protect bitstreams against unauthorized access, Certus-NX FPGAs support AES-256 encryption with ECDSA; they are currently the smallest FPGAs on the market to support ECDSA.
- Ease of use/design – Lattice Radiant® and Lattice Propel™ software tools help simplify and accelerate automotive system design. Certus-NX FPGAs are also supported by the Lattice mVision™ and Lattice sensAI™ solution stacks so designers can leverage the stacks’ modular hardware platforms, reference designs, neural network IP cores, and custom design services to accelerate automotive vision system design.
Automotive-grade versions of Certus-NX FPGAs are now sampling with select customers. For more information about the Lattice technologies mentioned above, please visit:
- www.latticesemi.com/Certus-NX
- www.latticesemi.com/LatticeNexus
- www.latticesemi.com/LatticeRadiant
- www.latticesemi.com/Propel
- www.latticesemi.com/mVision
- www.latticesemi.com/sensAI
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.
For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, Twitter, Facebook, YouTube, WeChat, Weibo, or Youku.
Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005002/en/
Contact information
MEDIA CONTACT:
Sophia Hong
Lattice Semiconductor
503-268-8786
Sophia.Hong@latticesemi.com
INVESTOR CONTACT:
Rick Muscha
Lattice Semiconductor
408-826-6000
Rick.Muscha@latticesemi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
